FDA Approves VENCLEXTA — AbbVie Inc.

# FDA Approves AbbVie's VENCLEXTA (venetoclax) for Chronic Lymphocytic Leukemia AbbVie Inc. received FDA approval for VENCLEXTA (venetoclax), an oral BCL-2 inhibitor for chronic lymphocytic leukemia, positioning the company to capture significant market share in the targeted oncology segment and potentially establishing a new standard of care in hematologic malignancies. The approval represents a major expansion of AbbVie's oncology portfolio and is expected to generate substantial revenue growth as the drug addresses a previously under